Key result
Accelerated cardiovascular aging on peri-aortic adipose radiomics is linked to ~51% higher MACE risk.
Why the study?
Chronological age is central to CVD risk estimation but poorly reflects interindividual heterogeneity in cardiovascular aging.
Does a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age biomarker improve risk stratification for incident MACE compared to chronological age?
Cohort (n=48,665)
Yes
Does a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age biomarker improve risk stratification for incident MACE compared to chronological age?
Hazard Ratio: 1.51 (95% CI 1.37–1.66)
p-value: p=<0.001
An AI-driven radiomic biomarker of peri-aortic adipose tissue from routine chest CT improves cardiovascular risk stratification and reclassification beyond chronological age.
May refine MACE stratification on routine CT beyond chronological age; extends radiomic tools but requires prospective validation before practice change.
Background and Aims Chronological age is central to cardiovascular disease (CVD) risk estimation but poorly reflects interindividual heterogeneity in cardiovascular aging. This study developed a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age (CV-Age) biomarker from routine chest CT and tested whether the PAAT age gap (ΔAge = CV-Age − chronological age) stratifies major adverse cardiovascular events (MACE) and improves risk classification. Methods Four chest CT cohorts with different protocols were utilized to train (n = 4451) and externally validate (n = 44 214) a CV-Age model. Associations between ΔAge decile groups (resilient ≤10th; accelerated ≥90th) and incident 5-point MACE (myocardial infarction, stroke, revascularization, heart failure, and death) were assessed using survival models. Clinical utility was evaluated by substituting CV-Age for chronological age in PREVENT to quantify risk reclassification. Results A 31-feature radiomic signature capturing PAAT volume, attenuation, and texture heterogeneity predicted age with good accuracy (training MAE 2.2 years; primary external validation MAE 2.7 years). In a separate higher-risk cohort, predictions showed a positive ΔAge (median +5.4 years), reflecting elevated baseline cardiovascular burden. ΔAge-stratified event-free survival differed across groups (log-rank P < .001); compared with normative agers, accelerated agers had higher MACE risk (HR 1.51, 95% CI 1.37–1.66), and resilient agers had lower risk (HR 0.70, 0.63–0.77). Substituting CV-Age into PREVENT improved risk reclassification (categorical NRI +0.03, P < .01, continuous NRI +0.04, P < .05). Conclusions Radiomic profiling of PAAT on routine chest CT yields a scalable imaging biomarker of cardiovascular aging. CV-Age can help improve identification of higher-risk individuals missed by age-driven risk estimation, supporting its role as a risk-enrichment tool.
No takes yet. Share an insight, caveat, or question.
Lebowitz et al. (2026) conducted a cohort in Cardiovascular aging (n=48,665). Accelerated cardiovascular aging (positive PAAT age gap) vs. Normative agers was evaluated on Incident 5-point MACE (myocardial infarction, stroke, revascularization, heart failure, and death) (HR 1.51, 95% CI 1.37-1.66, p=<0.001). Accelerated cardiovascular aging, assessed via a peri-aortic adipose tissue radiomic biomarker, was associated with higher MACE risk compared with normative agers (HR 1.51; 95% CI 1.37-1.66).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: